Skip to content
Screener

Enliven Therapeutics ELVN Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Pfizer logo
PfizerPFE
-$2.86B+45.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$223.93M+22,903%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$49.29M+273%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$7.92M+751%
CTO
Citius Oncology, Inc.CTOR
$15.13M+299%

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$4.42B+297%
Enterprise value$4.28B+332%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211982
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Net cash provided by investing activities42,5261,427
Cash flows from financing activities:
Proceeds from exercise of stock options10,053234
Net cash provided by financing activities10,053234
Net increase (decrease) in cash, cash equivalents and restricted cash33,288(22,466)
Cash, cash equivalents and restricted cash at the beginning of the period98,896124,171
Cash, cash equivalents and restricted cash at the end of the period$132,184$101,705
Supplemental disclosure of noncash investing and financing activities:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Enliven Therapeutics's financing cash flow?
Enliven Therapeutics (ELVN) reported financing cash flow of $10.05M in Q1 2026.
How has Enliven Therapeutics's financing cash flow changed year-over-year?
Enliven Therapeutics's financing cash flow increased by 4196.2% year-over-year, from $234K to $10.05M.
What is the long-term trend for Enliven Therapeutics's financing cash flow?
Over 3 years (2021 to 2025), Enliven Therapeutics's financing cash flow has grown at a 64.7% compound annual growth rate (CAGR), from $49.11M to $219.24M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Enliven Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude